摘要
目的:分别给予新诊断的复杂部分性发作癫痫患者不同的新型抗癫痫药单药治疗,比较4种抗癫痫新药的总有效率和一年保留率。方法:对253例新诊断的复杂部分性发作及复杂部分性发作继发全面性发作癫痫患者随机给予奥卡西平、托吡酯、左乙拉西坦、拉莫三嗪单药治疗,比较其总有效率和一年保留率,并分析停药原因。结果:4种抗癫痫新药控制癫痫的疗效基本一致,总有效率为75.4%～87.1%,无统计学差异。拉莫三嗪的保留率最高(88.6%),其次为左乙拉西坦(85.3%),托吡酯为68.5%,奥卡西平最低(61.4%)。拉莫三嗪与其他3种抗癫痫新药的保留率有统计学差异(P<0.05),其他3种药物之间无统计学差异。停药或换药的主要原因是癫痫控制无效或加重(28例,42.4%);其次是不良反应(13例,19.7%)及药物价格(10例,15.2%)。结论:4种抗癫痫新药的有效性无明显优劣差异,拉莫三嗪的一年保留率最高,停药原因主要为药物疗效不佳和不良反应。
Objective： To compare the total effective rates and one-year-retention rate of new antiepileptic drugs（AEDs）,respectively,as an initial monotherapy in complex partial epilepsy.Methods： Totally 253 patients who were newly diagnosed with complex partial epilepsy/complex partial secondary generalized seizure were randomized to be treated with oxcarbazepine（OXC）,topiramate（TPM）,levetiracetam（LEV） and lamotrigine（LTG） as initiation and early monotherapy.Their total effective rate and one-year-retention rate after 1 year were compared.The cause of drug withdrawal was analyzed.Results： The total effective rate in the 4 groups with new AEDs was from 75.4% to 87.1%,and there was no statistically significant difference.The one-year-retention rate of LTG was the highest（88.6%） followed by LEV（85.3%） and TPM（68.5%）,and OXC was the lowest（61.4%）.The highest retention rate with LTG was significantly different from the others,and there was no statistical difference among other three AEDs.The primary cause of drug withdrawal was seizure-control ineffectiveness（28,42.4%）,adverse effects（13,19.7%） and price（10,15.2%）.Conclusion： The effectiveness of the new AEDs has no obvious difference.The retention rate of LTG is the highest.The primary causes of drug withdrawal are lack of efficacy and adverse effects.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2012年第11期1265-1268,共4页
Chinese Journal of New Drugs
